Federal Circuit Affirms in Norwich Pharmaceuticals v. Salix: Key Lessons from a High-Stakes Rifaximin Patent Battle
What would you like to do next?
Choose your path based on your current needs:
Learn from this case
Understand the legal analysis, timeline, and key takeaways
RecommendedCheck my generic product’s risk
Run FTO analysis for your own generic drug or technology
Explore patent landscape
View related patents and competitive intelligence
📋 Case Summary
| Case Name | Norwich Pharmaceuticals, Inc. v. Salix Pharmaceuticals, Inc. |
| Case Number | 23-1952 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District Court |
| Duration | May 2023 – April 2024 317 days |
| Outcome | Defendant Win — Affirmance |
| Patents at Issue | |
| Accused Products | Norwich’s Proposed Generic Rifaximin 550 mg Tablets |
Case Overview
The Parties
⚖️ Plaintiff
Generic drug developer that sought regulatory approval to market a generic version of Rifaximin 550 mg tablets.
🛡️ Defendant
A subsidiary of Bausch Health Companies, holds the approved NDA for Xifaxan (rifaximin). Co-defendants Bausch Health Ireland, Ltd. and Alfasigma, S.p.A. hold licensing interests.
Patents at Issue
This case involved an exceptional 29 U.S. patents covering Rifaximin 550 mg tablets. The portfolio spans various aspects of the drug, from its chemical forms to its usage.
- • US7612199, US9271968, US8518949 — covering rifaximin polymorphic forms
- • US8158644, US10314828, US7902206 — directed to pharmaceutical compositions and dosing regimens
- • US10709694, US8193196, US9629828 — covering treatment methods for IBS-D and hepatic encephalopathy
- • Additional patents spanning formulation chemistry, synthesis methods, and clinical use protocols
Developing a generic drug?
Check if your pharmaceutical formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a clean affirmance: “THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.” The appeal was ultimately dismissed, leaving the lower court’s findings in favor of the defendants intact. No specific damages figure was publicly disclosed in available case records, consistent with Hatch-Waxman litigation where the primary remedy is injunctive — blocking generic market entry rather than monetary damages.
Key Legal Issues
The case proceeded as a classic Hatch-Waxman infringement action, triggered by Norwich’s ANDA Paragraph IV certification asserting patent invalidity or non-infringement. Under 35 U.S.C. § 271(e)(2), filing an ANDA with a Paragraph IV certification constitutes an act of patent infringement. With 29 patents at issue, the district court’s analysis almost certainly involved claim construction, validity challenges, and infringement analysis. The Federal Circuit’s affirmance signals that Norwich failed to demonstrate reversible error on any of these grounds.
Freedom to Operate (FTO) & Strategic Implications
This case highlights critical IP risks in pharmaceutical product development and generic entry. Choose your next step:
📋 Learn from This Pharma Patent Battle
Understand the specific risks and implications from this pharmaceutical litigation.
- View all 29 asserted patents in this portfolio
- See which companies are active in Rifaximin IP
- Understand polymorph and method-of-use claims
🔍 Assess My Generic Product’s FTO
Run a comprehensive FTO analysis for your own generic drug formulation or technology.
- Input your product description or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Areas
Polymorph & method-of-use claims
29 Asserted Patents
In Rifaximin 550mg portfolio
Limited Design-Around
Especially for polymorph patents
✅ Key Takeaways
Federal Circuit affirmed district court findings across a 29-patent pharmaceutical portfolio — demonstrating appellate deference in complex Hatch-Waxman matters.
Search related case law →Portfolio breadth, not just individual patent strength, is increasingly decisive in blocking generic entry.
Explore precedents →Co-defendant coordination between NDA holder and licensees is strategically essential for comprehensive standing.
Analyze co-defendant strategies →Frequently Asked Questions
The case involved 29 U.S. patents (including US7612199, US9271968, US8518949, and others) covering rifaximin polymorphic forms, pharmaceutical compositions, and treatment methods for IBS-D and hepatic encephalopathy.
The Federal Circuit affirmed the lower court’s ruling on April 11, 2024, dismissing Norwich’s appeal and leaving intact the infringement findings that protect Salix’s Rifaximin 550 mg tablet patents.
The case underscores the strategic value of large, multi-family patent portfolios in Hatch-Waxman litigation, making it significantly harder for generic manufacturers to clear all patent hurdles necessary for market entry.
Generic manufacturers challenging broad pharmaceutical patent portfolios, especially those involving polymorphs, should conduct rigorous pre-litigation invalidity analysis and consider Inter Partes Review (IPR) petitions at the PTAB as a potential alternative or parallel strategy.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 23-1952
- U.S. Patent and Trademark Office — Patent Full-Text Database
- U.S. Food & Drug Administration — Hatch-Waxman Act
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence Solutions for Pharmaceuticals
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For detailed case records, visit PACER or search patent numbers on the USPTO Patent Full-Text Database.